Lisata Therapeutics Inc investor relations material

Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing cellular therapies to reverse disease, promote regeneration and halt disease progression. Its product candidates include HONEDRA, a cell therapy product candidate that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease; AB1250-H, an investigational drug product candidate for acute myocardial infarction (AMI) patients who have undergone percutaneous coronary intervention (PCI); and VB6100, an investigational gene therapy product candidate designed to treat demyelinating disorders such as multiple sclerosis